News | August 10, 2008

Sorin Gets FDA Approval For World’s Smallest Implantable Dual Chamber Pacemaker

August 11, 2008 - The Sorin Group said last week the FDA approved the REPLY family of dual and single chamber pacemakers, with the world’s smallest dual chamber pacemaker at 8cc’s.

The company said the device is designed to reduce ventricular pacing and promote natural cardiac function. REPLY integrates Sorin Group’s new proprietary SafeR pacing mode. The technology builds on the Sorin Group’s AAISafeR pacing mode first introduced in Europe in September 2003 and in the U.S. in May 2005. AAISafeR switches from AAI to DDD in case of AV block detection, and has been shown to reduce unnecessary pacing in both sinus node disease and unselected AV block patients. The company said delivering unnecessary pacing to the right ventricle has been shown to significantly enhance the risk of patients developing heart failure and atrial fibrillation2.

In addition to SafeR, the REPLY pacemaker delivers automatic features such as SmartCheck, which lets the user automate follow up tests and provides comprehensive data reporting and recommendations.

Dr. Randy Lieberman, director of electrophysiology at Harper University Hospital and assistant professor of medicine at Wayne State University School of Medicine in Detroit, implanted the first Reply pacemaker in the U.S.

“The updated 2008 ACC/AHA Guidelines for Device-Based Therapy highlight the new standard of care in pacing, which is to minimize unnecessary ventricular pacing,” Dr. Lieberman said. “The Reply pacemaker was the right choice for this patient. Pacemaker options that only offer AV delay or AV search hysteresis do not eliminate frequent ventricular pacing for a significant number of patients. It’s important to know that down-sized devices do not mean that physicians have to compromise. Reply provides the output, longevity and pacing algorithms that physicians are looking for in a pacemaker.”

The REPLY pacemaker will be distributed in the U.S. by ELA Medical Inc., a Sorin Group Company.

For more information: www.sorin.com

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population
News | Atrial Fibrillation| July 03, 2017
Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in...
Sponsored Content | Videos | Cardiovascular Ultrasound| June 29, 2017
Leyla Elif Sade, M.D., MESC, professor of cardiology at Başkent University, Ankara, Turkey, discusses use of echo for
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Overlay Init